Neogenomics (NEO) Other Non-Current Liabilities (2017 - 2026)
Neogenomics filings provide 10 years of Other Non-Current Liabilities readings, the most recent being $12.0 million for Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 0.91% to $12.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $12.0 million, a 0.91% increase, with the full-year FY2025 number at $12.1 million, up 2.52% from a year prior.
- Other Non-Current Liabilities hit $12.0 million in Q1 2026 for Neogenomics, roughly flat from $12.1 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $14.2 million in Q3 2022 to a low of $11.5 million in Q2 2024.
- Median Other Non-Current Liabilities over the past 5 years was $13.0 million (2024), compared with a mean of $12.7 million.
- Biggest five-year swings in Other Non-Current Liabilities: soared 281.47% in 2022 and later fell 11.4% in 2024.
- Neogenomics' Other Non-Current Liabilities stood at $13.1 million in 2022, then dropped by 0.16% to $13.0 million in 2023, then dropped by 9.68% to $11.8 million in 2024, then increased by 2.52% to $12.1 million in 2025, then decreased by 0.32% to $12.0 million in 2026.
- The last three reported values for Other Non-Current Liabilities were $12.0 million (Q1 2026), $12.1 million (Q4 2025), and $12.0 million (Q3 2025) per Business Quant data.